antibodies excision repair cross complementing gene 1 (ercc1)  (Proteintech)

Journal: ESMO Open

Article Title: Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial

doi: 10.1016/j.esmoop.2021.100249

Figure Lengend Snippet: Consolidated Standards of Reporting Trials diagram. ERCC1, excision repair cross-complementation group 1; IHC, immunohistochemistry; TS, thymidylate synthase.

Article Snippet: Immunohistochemical staining was carried out using the D6G6 anti-excision repair cross-complementation group 1 (ERCC1) monoclonal antibody (Cell Signaling Technology, Danvers, MA), the TS106 anti-TS monoclonal antibody (Dako, Glostrup, Denmark), and a DAKO Link 48 system (Dako).

Techniques: Immunohistochemistry

Journal: ESMO Open

Article Title: Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial

doi: 10.1016/j.esmoop.2021.100249

Figure Lengend Snippet: Survival outcomes according to excision repair cross-complementation group 1 (ERCC1) and thymidylate synthase (TS) expression. (A) Immunohistochemistry for TS expression in soft tissue sarcoma (STS). Representative images of both TS-negative (H-score: 0, ×200) and TS-positive (H-score: 10 and 200, ×200) sections. (B) Immunohistochemistry for ERCC1 expression in sections from patients with STS. Representative images of ERCC1-negative (H-score: 0, ×200) and ERCC1-positive sections (H-score: 15 and 200, ×200). (C) Kaplan–Meier analysis of overall survival (OS) according to TS expression, determined using a cut-off point of median H-score 25. (D) Kaplan–Meier analysis of OS according to ERCC1 expression, determined using a cut-off point of median H-score 60.

Article Snippet: Immunohistochemical staining was carried out using the D6G6 anti-excision repair cross-complementation group 1 (ERCC1) monoclonal antibody (Cell Signaling Technology, Danvers, MA), the TS106 anti-TS monoclonal antibody (Dako, Glostrup, Denmark), and a DAKO Link 48 system (Dako).

Techniques: Expressing, Immunohistochemistry

Journal: Molecular medicine reports

Article Title: MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.

doi: 10.3892/mmr.2018.9730

Figure Lengend Snippet: Figure 4. Gene expression induced by U0126 combined with or without oxaliplatin/5‑FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT‑qPCR following treatment with U0126 and/or 5‑FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β‑actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5‑FU, respectively. **P<0.01 vs. control group; ##P<0.01 vs. oxaliplatin/5‑FU‑treated group. 5‑FU, 5‑fluorouracil; ERCC1, excision repair cross‑complementation group 1; TYMS, thymidylate synthase; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.

Article Snippet: Excision repair cross-complementation group 1 (ERCC1) rabbit polyclonal antibody (cat. no. 14586‐1‐AP) and TYMS rabbit polyclonal antibody (cat. no. 15047‐1‐AP) were purchased from ProteinTech Group, Inc. (Wuhan, China).

Techniques: Gene Expression, Standard Deviation, Western Blot, Expressing, Control, Polymerase Chain Reaction

Journal: Molecular Medicine Reports

Article Title: MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5-fluorouracil in MEK1 Q56P-mutant colorectal cancer cells

doi: 10.3892/mmr.2018.9730

Figure Lengend Snippet: Gene expression induced by U0126 combined with or without oxaliplatin/5-FU. (A) ERCC1 mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or oxaliplatin. (B) TYMS mRNA levels in SW48 cells were examined by RT-qPCR following treatment with U0126 and/or 5-FU. The graph depicts the fold change in ERCC1/TYMS levels normalized to β-actin levels. Data are presented as means ± standard deviation. Western blot analysis results of (C) ERCC1 and (D) TYMS protein expression levels in cells treated with U0126 in combination with oxaliplatin or 5-FU, respectively. **P<0.01 vs. control group; ## P<0.01 vs. oxaliplatin/5-FU-treated group. 5-FU, 5-fluorouracil; ERCC1, excision repair cross-complementation group 1; TYMS, thymidylate synthase; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

Article Snippet: Excision repair cross-complementation group 1 (ERCC1) rabbit polyclonal antibody (cat. no. 14586-1-AP) and TYMS rabbit polyclonal antibody (cat. no. 15047-1-AP) were purchased from ProteinTech Group, Inc. (Wuhan, China).

Techniques: Gene Expression, Quantitative RT-PCR, Standard Deviation, Western Blot, Expressing, Control, Reverse Transcription, Real-time Polymerase Chain Reaction